Applications of Yttrium-90 (⁹⁰Y) in Hepatocellular Carcinoma

References

• Villanueva A. Hepatocellular Carcinoma. New Engl J Med. 2019;380(15):1450–1462. doi:10.1056/NEJMra1713263
   PubMed Web of Science ®Google Scholar
• Loomba R, Lim JK, Patton H, et al. AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: expert Review. Gastroenterology. 2020;158(6):1822–1830. doi:10.1053/j.gastro.2019.12.053
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca a Cancer J Clinicians. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Wigg AJ, Palumbo K, Wigg DR. Radiotherapy for hepatocellular carcinoma: systematic review of radiobiology and modelling projections indicate reconsideration of its use. J Gastroenterol Hepatol. 2010;25(4):664–671. doi:10.1111/j.1440-1746.2009.06126.x
   PubMed Web of Science ®Google Scholar
• Edeline J, Gilabert M, Garin E, et al. Yttrium-90 microsphere radioembolization for hepatocellular carcinoma. Liver Cancer. 2015;4(1):16–25. doi:10.1159/000343878
   PubMed Web of Science ®Google Scholar
• Levillain H, Bagni O, Deroose CM, et al. International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres. Eur J Nucl Med Mol Imaging. 2021;48(5):1570–1584. doi:10.1007/s00259-020-05163-5
   PubMed Web of Science ®Google Scholar
• Burrel M, Bermúdez P, Forner González A. Perspectives for yttrium-90 radioembolization as therapeutic option for hepatocellular carcinoma. Rev Esp Enferm Dig. 2022;114(4):195–197. doi:10.17235/reed.2022.8775/2022
   PubMed Web of Science ®Google Scholar
• Filippi L, Schillaci O, Cianni R, et al. Yttrium-90 resin microspheres and their use in the treatment of intrahepatic cholangiocarcinoma. Future Oncol. 2018;14(9):809–818. doi:10.2217/fon-2017-0443
   PubMed Web of Science ®Google Scholar
• Steinhoff KG, Petersen TO, Purz S, et al. Yttrium-90 radioembolisation-induced abscopal effect on hepatocellular carcinoma. J Digestive Dis. 2022;23(4):237–239. doi:10.1111/1751-2980.13092
   PubMed Web of Science ®Google Scholar
• Fong ZV, Qadan M. Yttrium-90 radiation lobectomy for initially unresectable hepatocellular carcinoma: a treatment paradigm shift? Surgery. 2021;169(5):1052–1053. doi:10.1016/j.surg.2020.12.041
   PubMed Web of Science ®Google Scholar
• Gulec SA. Y-90 Radiomicrosphere Therapy for Colorectal Cancer Liver Metastases. Sem Nuclear Med. 2016;46(2):126–134. doi:10.1053/j.semnuclmed.2015.10.008
   PubMed Web of Science ®Google Scholar
• Garin E, Tselikas L, Guiu B, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6(1):17–29. doi:10.1016/S2468-1253(20)30290-9
   PubMed Web of Science ®Google Scholar
• Murthy R, Nunez R, Szklaruk J, et al. Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. Radiographics. 2005;25(Suppl 1):S41–55. doi:10.1148/rg.25si055515
   PubMedGoogle Scholar
• Campbell AM, Bailey IH, Burton MA. Analysis of the distribution of intra-arterial microspheres in human liver following hepatic yttrium-90 microsphere therapy. Phys Med Biol. 2000;45(4):1023–1033. doi:10.1088/0031-9155/45/4/316
   PubMed Web of Science ®Google Scholar
• Vilgrain V, Pereira H, Assenat E, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18(12):1624–1636. doi:10.1016/S1470-2045(17)30683-6
   PubMed Web of Science ®Google Scholar
• Braat MN, Braat AJ, Lam MG. Toxicity comparison of yttrium-90 resin and glass microspheres radioembolization. Quarterly j Nuclear Med Mol Imaging. 2022;6:1827–1936.
   Google Scholar
• Niu H, Wang Z, Gao S, et al. Application and progress of yttrium 90 radioactive microspheres in hepatic malignancies %. J Liver Cancer e-J. 2021;8(4):36–40.
   Google Scholar
• Wang EA, Broadwell SR, Bellavia RJ, et al. Selective internal radiation therapy with SIR-Spheres in hepatocellular carcinoma and cholangiocarcinoma. J gastrointestinal oncol. 2017;8(2):266–278. doi:10.21037/jgo.2016.11.08
   PubMed Web of Science ®Google Scholar
• Yan C, Wang YH, Yu Q, et al. Clonorchis sinensis excretory/secretory products promote the secretion of TNF-alpha in the mouse intrahepatic biliary epithelial cells via Toll-like receptor 4. Parasites Vectors. 2015;8(1):559. doi:10.1186/s13071-015-1171-0
   PubMedGoogle Scholar
• Giammarile F, Bodei L, Chiesa C, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging. 2011;38(7):1393–1406. doi:10.1007/s00259-011-1812-2
   PubMed Web of Science ®Google Scholar
• Salem R, Johnson GE, Kim E, et al. Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: the LEGACY Study. Hepatology. 2021;74(5):2342–2352. doi:10.1002/hep.31819
   PubMed Web of Science ®Google Scholar
• Jeyarajah DR, Doyle MBM, Espat NJ, et al. Role of yttrium-90 selective internal radiation therapy in the treatment of liver-dominant metastatic colorectal cancer: an evidence-based expert consensus algorithm. J Gastrointest Oncol. 2020;11(2):443–460. doi:10.21037/jgo.2020.01.09
   PubMed Web of Science ®Google Scholar
• Guiu B, Garin E, Allimant C, et al. TARE in Hepatocellular Carcinoma: from the Right to the Left of BCLC. Cardiovascular Interventional Radiol. 2022;45(11):1599–1607. doi:10.1007/s00270-022-03072-8
   PubMed Web of Science ®Google Scholar
• Lee EJ, Chung HW, Jo JH, et al. Radioembolization for the Treatment of Primary and Metastatic Liver Cancers. Nuclear Med Mol Imaging. 2019;53(6):367–373. doi:10.1007/s13139-019-00615-9
   PubMed Web of Science ®Google Scholar
• Memon K, Lewandowski RJ, Kulik L, et al. Radioembolization for primary and metastatic liver cancer. Sem rad oncol. 2011;21(4):294–302. doi:10.1016/j.semradonc.2011.05.004
   PubMed Web of Science ®Google Scholar
• Shuxun L, Jiabei W, Lianxin L. Yttrium 90 microspheres selective radiotherapy embolisation in the treatment of hepatocellular carcinoma. J Progress Modern General Surgery China. 2019;22(7):540–2, 82.
   Google Scholar
• Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolisation for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010;138(1):52–64. doi:10.1053/j.gastro.2009.09.006
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, Elsayed Z. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev. 2020;11(11):Cd011313. doi:10.1002/14651858.CD011313.pub4
   PubMedGoogle Scholar
• Hilgard P, Hamami M, Fouly AE, et al. Radioembolisation with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology. 2010;52(5):1741–1749. doi:10.1002/hep.23944
   PubMed Web of Science ®Google Scholar
• Mazzaferro V, Sposito C, Bhoori S, et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology. 2013;57(5):1826–1837. doi:10.1002/hep.26014
   PubMed Web of Science ®Google Scholar
• Chow R, Simone CB, Jairam MP, et al. Radiofrequency ablation vs radiation therapy vs transarterial chemoembolisation vs yttrium 90 for local treatment of liver cancer - a systematic review and network meta-analysis of survival data. Acta oncologica. 2022;61(4):484–494. doi:10.1080/0284186X.2021.2009563
   PubMed Web of Science ®Google Scholar
• Lobo L, Yakoub D, Picado O, et al. Unresectable Hepatocellular Carcinoma: radioembolisation Versus Chemoembolization: a Systematic Review and Meta-analysis. Cardiovascular Interventional Radiol. 2016;39(11):1580–1588. doi:10.1007/s00270-016-1426-y
   PubMed Web of Science ®Google Scholar
• Murali N, Mouli SK, Riaz A, et al. Extrahepatic Applications of Yttrium-90 Radioembolization. Sem interventional radiol. 2021;38(4):479–481. doi:10.1055/s-0041-1735573
   PubMedGoogle Scholar
• Gabr A, Kulik L, Mouli S, et al. Liver Transplantation Following Yttrium-90 Radioembolisation: 15-Year Experience in 207-Patient Cohort. Hepatology. 2021;73(3):998–1010. doi:10.1002/hep.31318
   PubMed Web of Science ®Google Scholar
• Dhondt E, Lambert B, Hermie L, et al. (90)Y Radioembolization versus Drug-eluting Bead Chemoembolization for Unresectable Hepatocellular Carcinoma: results from the TRACE Phase II Randomised Controlled Trial. Radiology. 2022;303(3):699–710. doi:10.1148/radiol.211806
   PubMed Web of Science ®Google Scholar
• Hamad A, Aziz H, Kamel IR, et al. Yttrium-90 Radioembolisation: current Indications and Outcomes. J Gastrointestinal Surg. 2022;12:1873–4626.
   Google Scholar
• Yu CY, Huang PH, Tsang LL, et al. Yttrium-90 Radioembolization as the Major Treatment of Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2023;10:17–26. doi:10.2147/JHC.S385478
   PubMed Web of Science ®Google Scholar
• Kim HC. Role of Yttrium-90 Radioembolization for Colorectal Hepatic Metastasis. Korean j radiol. 2022;23(2):156–158. doi:10.3348/kjr.2021.0867
   PubMed Web of Science ®Google Scholar
• Mehta N, Yao FY. Liver Transplantation After Downstaging of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus Using Yttrium-90 Radioembolisation: pipe Dream or Reality? Liver Transplantation. 2021;27(12):1706–1708. doi:10.1002/lt.26302
   PubMed Web of Science ®Google Scholar
• Titano JJ, Kim E, Patel RS. Yttrium-90 Complications: prevention and Management. Tech Vasc Interv Radiol. 2019;22(2):87–92. doi:10.1053/j.tvir.2019.02.010
   PubMed Web of Science ®Google Scholar
• Kim HC, Kim GM. Radiation pneumonitis following Yttrium-90 radioembolization: a Korean multicenter study. Front Oncol. 2023;13:977160. doi:10.3389/fonc.2023.977160
   PubMed Web of Science ®Google Scholar
• Zhiyuan Z, Zhiping Y. Progress in the application of yttrium 90 radioactive microspheres for the treatment of liver malignant tumours. Fudan J. 2020;47(4):622–627.
   Google Scholar
• Gupta AN, Gordon AC, Gabr A, et al. Yttrium-90 Radioembolization of Unresectable Intrahepatic Cholangiocarcinoma: long-Term Follow-up for a 136- Patient Cohort. Cardiovascular Interventional Radiol. 2022;45(8):1117–1128. doi:10.1007/s00270-022-03183-2
   PubMed Web of Science ®Google Scholar
• Kulik L, Vouche M, Koppe S, et al. Prospective randomized pilot study of Y90±sorafenib as bridge to transplantation in hepatocellular carcinoma [J]. J Hepatol. 2014;61(2):309–317. doi:10.1016/j.jhep.2014.03.023
   PubMed Web of Science ®Google Scholar
• Chow PK, Poon DY, Khin MW, et al. Multicenter phase II study of sequential radioembolisation-sorafenib therapy for inoperable hepatocellular carcinoma. PLoS One. 2014;9(3):e90909. doi:10.1371/journal.pone.0090909
   PubMed Web of Science ®Google Scholar
• Kodaira S, Morokoshi Y, Li HK, et al. Evidence of Local Concentration of α-Particles from (211)At-Labeled Antibodies in Liver Metastasis Tissue. J nuclear med. 2019;60(4):497–501. doi:10.2967/jnumed.118.216853
   PubMed Web of Science ®Google Scholar
• Poty S, Francesconi LC, Mcdevitt MR, et al. α-Emitters for Radiotherapy: from Basic Radiochemistry to Clinical Studies-Part 1. J nuclear med. 2018;59(6):878–884. doi:10.2967/jnumed.116.186338
   PubMed Web of Science ®Google Scholar
• Tafreshi NK, Doligalski ML, Tichacek CJ, et al. Development of Targeted Alpha Particle Therapy for Solid Tumors. Molecules. 2019;24(23):56.
   Web of Science ®Google Scholar